Isvoranu G, Chiritoiu-Butnaru M
Front Immunol. 2024; 15:1369743.
PMID: 38638431
PMC: 11024325.
DOI: 10.3389/fimmu.2024.1369743.
Berger A, Colpitts S, Zych M, Paige C
Cancer Immunol Immunother. 2023; 72(8):2597-2612.
PMID: 37061631
PMC: 10991896.
DOI: 10.1007/s00262-023-03442-2.
Wu S, Sun R, Tan B, Chen B, Zhou W, Gao D
Front Cell Dev Biol. 2021; 9:779865.
PMID: 34869384
PMC: 8634682.
DOI: 10.3389/fcell.2021.779865.
Lorenzo-Herrero S, Lopez-Soto A, Sordo-Bahamonde C, Gonzalez-Rodriguez A, Vitale M, Gonzalez S
Cancers (Basel). 2019; 11(1).
PMID: 30597841
PMC: 6357056.
DOI: 10.3390/cancers11010029.
Zhang Y, Wang J, Wu D, Li M, Zhao F, Ren M
Onco Targets Ther. 2018; 11:2037-2050.
PMID: 29692616
PMC: 5901132.
DOI: 10.2147/OTT.S147855.
Deficiency of the immunostimulatory cytokine IL-21 promotes intestinal neoplasia via dysregulation of the Th1/Th17 axis.
Shapiro M, Nandi B, Gonzalez G, Prabhala R, Mashimo H, Huang Q
Oncoimmunology. 2017; 6(1):e1261776.
PMID: 28197386
PMC: 5283644.
DOI: 10.1080/2162402X.2016.1261776.
IL-21 Signaling in Immunity.
Leonard W, Wan C
F1000Res. 2016; 5.
PMID: 26966515
PMC: 4770986.
DOI: 10.12688/f1000research.7634.1.
IL-21: a pleiotropic cytokine with potential applications in oncology.
Croce M, Rigo V, Ferrini S
J Immunol Res. 2015; 2015:696578.
PMID: 25961061
PMC: 4413888.
DOI: 10.1155/2015/696578.
Effect of interleukin 21 and its receptor on CD8 T cells in the pathogenesis of diffuse large B-cell lymphoma.
Cha Z, Gu H, Guo H, Tu X, Zang Y, Zhao C
Oncol Lett. 2014; 8(1):421-425.
PMID: 24959288
PMC: 4063596.
DOI: 10.3892/ol.2014.2062.
IL-21 promotes CD4 T cell responses by phosphatidylinositol 3-kinase-dependent upregulation of CD86 on B cells.
Attridge K, Kenefeck R, Wardzinski L, Qureshi O, Wang C, Manzotti C
J Immunol. 2014; 192(5):2195-201.
PMID: 24470500
PMC: 3932810.
DOI: 10.4049/jimmunol.1302082.
Intestinal inflammation and colorectal cancer: a double-edged sword?.
Rizzo A, Pallone F, Monteleone G, Fantini M
World J Gastroenterol. 2011; 17(26):3092-100.
PMID: 21912451
PMC: 3158408.
DOI: 10.3748/wjg.v17.i26.3092.
Vaccines and immunotherapeutics for the treatment of malignant disease.
Aldrich J, Lowe D, Shearer M, Winn R, Jumper C, Kennedy R
Clin Dev Immunol. 2010; 2010:697158.
PMID: 20936120
PMC: 2948924.
DOI: 10.1155/2010/697158.
Immune activation in advanced cancer patients treated with recombinant IL-21: multianalyte profiling of serum proteins.
Dodds M, Frederiksen K, Skak K, Hansen L, Lundsgaard D, Thompson J
Cancer Immunol Immunother. 2008; 58(6):843-54.
PMID: 18925392
PMC: 11030868.
DOI: 10.1007/s00262-008-0600-8.
Interleukin 21: a cytokine/cytokine receptor system that has come of age.
Leonard W, Zeng R, Spolski R
J Leukoc Biol. 2008; 84(2):348-56.
PMID: 18467657
PMC: 2493068.
DOI: 10.1189/jlb.0308149.
Immunotherapy of neuroblastoma by an Interleukin-21-secreting cell vaccine involves survivin as antigen.
Croce M, Meazza R, Orengo A, Fabbi M, Borghi M, Ribatti D
Cancer Immunol Immunother. 2008; 57(11):1625-34.
PMID: 18324400
PMC: 11030971.
DOI: 10.1007/s00262-008-0496-3.
Role of IL-21 in immune-regulation and tumor immunotherapy.
Di Carlo E, de Totero D, Piazza T, Fabbi M, Ferrini S
Cancer Immunol Immunother. 2007; 56(9):1323-34.
PMID: 17447063
PMC: 11031117.
DOI: 10.1007/s00262-007-0326-z.
Interleukin 21 therapy increases the density of tumor infiltrating CD8+ T cells and inhibits the growth of syngeneic tumors.
Sondergaard H, Frederiksen K, Thygesen P, Galsgaard E, Skak K, Kristjansen P
Cancer Immunol Immunother. 2007; 56(9):1417-28.
PMID: 17285290
PMC: 11030032.
DOI: 10.1007/s00262-007-0285-4.
Increased level and longevity of protective immune responses induced by DNA vaccine expressing the HIV-1 Env glycoprotein when combined with IL-21 and IL-15 gene delivery.
Bolesta E, Kowalczyk A, Wierzbicki A, Eppolito C, Kaneko Y, Takiguchi M
J Immunol. 2006; 177(1):177-91.
PMID: 16785513
PMC: 2504862.
DOI: 10.4049/jimmunol.177.1.177.
Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model.
He H, Wisner P, Yang G, Hu H, Haley D, Miller W
J Transl Med. 2006; 4:24.
PMID: 16772043
PMC: 1502139.
DOI: 10.1186/1479-5876-4-24.
Immune enhancement and anti-tumour activity of IL-23.
Hao J, Shan B
Cancer Immunol Immunother. 2006; 55(11):1426-31.
PMID: 16676182
PMC: 11031071.
DOI: 10.1007/s00262-006-0171-5.